# SPRING MILL PHARMA INCORPORATED: Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | SPRING MILL PHARMA INCORPORATED |
| Location | MALVERN, PA |
| Project | Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii |
| Project number | 6R44AI181353-03 |
| Mechanism | R44 |
| Institute | National Institute of Allergy and Infectious Diseases |
| Award | $1,000,000 |
| Awarded | 2026-09-11 |
| Project period | 2024-04-01 to 2027-03-31 |
| UEI | UWZNAK5HJLN7 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11314526). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.